News

Under the terms of the option agreement, Celtic Therapeutics has an exclusive option to acquire and license rights to Resolvyx’s RX-10045, in all eye indications. RX-10045 is scheduled

TMX-67, an oral, once-daily, highly potent, non-purine selective inhibitor of xanthine oxidase, with a structure different from allopurinol, lowers the level of uric acid in the blood of

The company said that if the trial is successful, Verona will work to identify and develop a second generation of compounds with an improved profile. Verona Pharma CEO

Elan posted a net loss of $43.6m for the third quarter 2010, or $0.07 loss per diluted share, compared to net income of $52.3m, or $0.11 per diluted

Mylan has posted net earnings of $108.42m for the third quarter 2010, or $0.33 per diluted share, compared to net loss of $40.02m, or $0.13 loss per diluted

Treakisym is an anticancer agent that exhibits both nitrogen mustard-derived alkylating activity and antimetabolic-like activity. Treakisym is the subject of a licensing agreement concluded between Eisai and SymBio

Amgen and GlaxoSmithKline, who are co-marketing Prolia (denosumab), welcomed the NICE decision. GSK said that the guidance recommends denosumab as a treatment option for the prevention of osteoporotic

InSpire now supports Italian, Spanish, Portuguese, French, German, Dutch, English, Danish, Swedish, Norwegian and Icelandic as well as Malay and Swahili languages, with additional languages to be added

Aoxing Pharma has recently completed construction of chemical synthesis laboratories and pilot-manufacturing plant for the joint venture, which focuses on research, development, manufacturing and marketing of active pharmaceutical